Search PubMed⌕ Search

Biomedical subjects

S Ferrone

Publications and source records attributed to S Ferrone.

At least 361 records · Page 20Linked to original sources
PubMed1981

Cellular and molecular heterogeneity of H-2Kk antigens.

Up to 70% of mouse spleen cells expressing H-2Kk alloantigens reacted with the monoclonal anti-H-2Kk antibody 11-4.1 in an indirect rosetting assay. When the cells that rosetted with the monoclonal antibody 11-4.1 were removed by density centrifugation, the residual unreactive cells reacted with the polyclonal anti-H-2Kk alloantiserum D23 but not with the monoclonal antibody 11-4.1 indicating the existence of two cel populations. In sequential immunoprecipitation experiments, the glycoprotein fraction of NP40 extracts from H-2Kk cells, after removal of antigens reacting with the monoclonal antibody 11-4.1 still contained structures reactive with the alloantiserum. Therefore, there are at least two antigenically distinct H-2Kk molecules which are differentially expressed on two subpopulations of spleen cells.

Animals↗
PubMed1981

Persistence of cytotoxic antibodies to HLA-A,B,C antigens and to Ia-like antigens in parous women.

Cytotoxic antibodies to HLA-A,B,C and to Ia-like antigens were detected in about 8% of sera drawn from 1312 women several years after their last pregnancy. In the majority of sera anti Ia-like antigen antibodies were not associated with anti HLA-A,B,C antibodies. Persistence of both types of antibodies was not correlated with the number of pregnancies and with the time interval between the last immunizing stimulus and the drawing of the sample. Testing of the sera with a panel of HLA typed lymphocytes identified 20 sera specific for HLA-A,B alloantigens and 7 specific for Ia-like alloantigens.

Antibodies↗
PubMed1981

Serologic and immunochemical characterization of the specificity of four monoclonal antibodies to distinct antigenic determinants expressed on subpopulations of human Ia-like antigens.

Serologic and immunochemical assays showed that the monoclonal antibodies Q2/70, Q2/80, Q5/6, and Q5/13 react with human Ia-like antigens. Each monoclonal antibody recognizes distinct antigenic determinants that are different from those defining the serologic polymorphism of Ia-like antigens defined by conventional alloantisera and are expressed on subpopulations of Ia-like antigens. The determinants recognized by the MoAb Q2/70 and Q5/13 are expressed on all HLA-DR allospecificities tested, whereas those reacting with the MoAb Q2/80 and Q5/6 are not detectable on HLA-DR5 and HLA-DR7 allospecificities, respectively.

Antibodies↗
PubMed1981

Serological and immunochemical analysis of the specificity of xenoantiserum 8986 elicited with hybrids between human melanoma cells and murine fibroblasts.

Antisera were elicited in rabbits with hybrids derived from the fusion of human melanoma cells with murine fibroblasts. Following absorption with cultured human lymphoid cells, Xenoantiserum 8986 reacts with cultured human melanoma cells and other tumors of nonlymphoid origin. Rosette inhibition assays showed that the xenoantiserum reacts with structures which carry the determinants recognized by the monoclonal antibodies 165.28T and 653.25N and which are recognized by a xenoantiserum elicited with cultured human melanoma cells. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of the immune complexes formed by reacting spent medium of cultured melanoma cells with Xenoantiserum 8986 showed that the antiserum contains antibodies reacting with a M.W. 240,000 melanoma-associated antigen and a M.W. 94,000 melanoma-associated antigen.

Animals↗
PubMed1981

Characterization of monoclonal antibodies to human melanoma-associated antigens.

The hybridomas No. 165.28T, No. 473.54S, and No. 653.25N derived from the fusion of myeloma cells with splenocytes from mice immunized with cultured human melanoma cells secreted monoclonal antibodies recognizing antigenic determinants maximally expressed on cultured human melanoma cells and freshly explanted melanoma cells. Monoclonal antibody No. 376.74T reacted also with carcinoma cell lines but with a significantly lower titer. Rosette inhibition assay showed that these antigenic determinants were expressed on antigenic structures, which are not associated with beta 2 microglobulin and histocompatibility antigens. Two monoclonal antibodies recognized the same or closely associated antigenic determinants, and the remaining two monoclonal antibodies reacted with distinct antigenic determinants. All four monoclonal antibodies could mediate antibody-dependent cellular cytotoxicity of cultured melanoma cells, but none could mediate complement-dependent cytotoxicity.

Animals↗
PubMed1981

T lymphocyte-mediated cytotoxicity against autologous EBV-genome-bearing B cells.

We have stimulated human peripheral blood lymphocytes in vitro with autologous EBV-infected or noninfected B cells. A cytotoxic response was obtained only when virally infected cells were used. The activity of the effector cells was restricted by the major histocompatibility complex and was directed against EBV-genome-bearing targets. The highest cytolytic response was obtained when lymphocytes of individuals previously exposed to the virus (EBV-VCA positive) were used. Lymphocytes of noninfected donors (EBV-VCA negative) gave a low response; the relative frequency of their effector cells was at least 4-fold lower. Lymphocytes of newborns did not respond. The cytotoxic activity was mediated by T lymphocytes of the cytotoxic/suppressor subset, as determined by cytofluorographic analysis and antibody plus complement-mediated lysis, using monoclonal antibodies to human lymphocyte surface antigen.

Antibodies↗
PubMed1981

Common antigenic determinants on human melanoma, glioma, neuroblastoma, and sarcoma cells defined with monoclonal antibodies.

Antigenic determinants that are common to melanomas, gliomas, neuroblastomas, and sarcomas but that are minimally or not detectably expressed by adult tissues were defined with monoclonal antibodies. Quantitative absorption of monoclonal antibody (Ab 165) with adult tissues followed by testing on antigen-positive UCLA-SO-M14 melanoma cells did not demonstrate antigenic determinant (Ag 165) in brain, lung, liver, kidney, intestine, adrenal, and muscle, Absorption of Ab 376 demonstrated Ag 376 in adult lung but minimal or no antigen in other tissues. Both antigens were associated with a variety of fetal tissues. Assessment of 28 human tumor cell lines with the 131I-staphylococcal Protein A-binding test demonstrated that Ab 165 reacted strongly with melanomas and gliomas and weakly with sarcomas. Ab 376 reacted strongly with melanomas, gliomas, neuroblastomas, and sarcomas. Neither of these antibodies reacted appreciably with carcinoma or teratoma cell lines. Absorption of Ab 165 and Ab 376 with noncultured tumors demonstrated that melanomas, sarcomas, and neuroblastomas can have greater quantities of these antigens in vivo than do normal adult tissues. Qualitative and quantitative antigenic heterogeneity within positive classes of tumors was demonstrated for both cultured and noncultured tumors. The differences in antigen expression in vivo between normal and neoplastic cells suggest potential value for these antibodies in immunodiagnosis and possibly immunotherapy.

Antibodies, Neoplasm↗
PubMed1981

Differential effect of interferon on the expression of tumor-associated antigens and histocompatibility antigens on human melanoma cells: relationship to susceptibility to immune lysis mediated by monoclonal antibodies.

Incubation of cultured human melanoma cells with human leukocyte interferon did not change the expression of melanoma-associated antigens (MAA) recognized by monoclonal antibodies and of Ia-like antigens but significantly increased the expression of HLA-A,B antigens and of beta 2-microglobulin (beta 2-mu). The effect is dependent on the dose of interferon and on the incubation time. Interferon-treated melanoma cells showed an increased susceptibility to lysis mediated by monoclonal antibodies to HLA-A,B antigens and to human beta 2-mu; on the other hand, interferon-treated melanoma cells did not change in their susceptibility to murine natural killer (NK) cell lysis and to immune lysis mediated by monoclonal antibodies to MAA and to Ia-like antigens, and they displayed a reduced susceptibility to human NK cell lysis. Therefore, the increased susceptibility of interferon-treated melanoma cells to lysis mediated by anti HLA-A,B and anti beta 2-mu monoclonal antibodies is likely to reflect the increase in cell surface expression of the corresponding antigens.

Animals↗
PubMed1981

Role of antigen density in immune lysis of interferon-treated human lymphoid cells: analysis with monoclonal antibodies to the HLA-A,B antigenic molecular complex and to Ia-like antigens.

Cultured human lymphoid WI-L2 cells incubated with human leucocyte interferon (final concentration 500 and 2000 U/ml) for 16 h at 37 degrees C acquire increased susceptibility to complement and cell-dependent lysis mediated by monoclonal antibodies to HLA-A,B antigens and to human beta 2-microglobulin but do not change in their susceptibility to immune lysis mediated by monoclonal antibodies to human Ia-like antigens. Changes in susceptibility to immune lysis of interferon-treated lymphoid cells are likely to reflect changes in antigen density, since binding assays with monoclonal antibodies and quantitative absorption assays with alloantisera have shown that the expression of HLA-A,B antigens and beta 2-microglobulin is significantly increased on interferon-treated lymphoid cells, whereas that of Ia-like antigens in not changed.

Antibodies, Monoclonal↗
PubMed1981

Analysis of human tumor cells for Ia-like antigens with monoclonal antibodies.

Cultured and noncultured human solid tumors were analyzed for expression of Ia-like antigens with the use of two monoclonal antibodies and a rabbit antiserum against human Ia-like antigens. Of 27 tumor cells tested, 3 melanomas bound antibodies [e.g., 21,563 cpm 131I-labeled staphylococcal protein A ([131I]SpA) with monoclonal antibody Q5/6], but 24 others (1 melanoma, 9 neuroblastomas, 1 medulloblastoma, 3 gliomas, 4 sarcomas, 2 colon carcinomas, 2 transitional cell carcinomas of the bladder, 1 teratoma, and 1 squamous cell carcinoma of the lung) did so minimally or not at all (0-427 cpm [131I]SpA with antibody Q5/6. Monoclonal antibody Q5/6 was quantitatively absorbed with homogenates of 32 noncultured tumors to determine if Ia-like antigens were expressed by neoplastic cells in vivo. Ten milligrams (wet wt) each of 5 of 7 noncultured melanomas removed more than 83% (median, 85%) of the antibody. In contrast, 10 mg each of 10 neuroblastomas, 7 carcinomas, 4 sarcomas, and 4 Wilms' tumors removed less than 47% (median, 19%) of the antibody; even 100 mg of these tumors removed less than 68% (median, 44%) of the antibody.

Antibodies↗
PubMed1981

Discordant expression of 2 Epstein-Barr virus-associated antigens, EBNA and RANA, in man-rodent somatic cell hybrids.

The Epstein Barr nuclear antigen (EBNA) and the rheumatoid arthritis nuclear antigen (RANA) develop in human B lymphocytes that have been infected and transformed by Epstein Barr virus (EBV). Antibodies to RANA and EBNA are found only in individuals with prior exposure to EBV. The purpose of the present studies was to determine the relation of the 2 antigens to each other and to EBV genetic material, in human-rodent somatic cell hybrids. Cultured human B lymphoblastoid cells, Raji, Daudi, and RPMI 4098 were fused with thymidine kinase-deficient mouse or hamster fibroblasts. After selection and cloning in ouabain-HAT medium, the hybrid nature of the surviving cells was confirmed by isozyme analysis. The hybrid clones were analyzed for EBNA by anti-complement im,munofluorescence, and for RANA by anti-immunoglobulin immunofluorescence and immunodiffusion. The results showed that RANA and EBNA segregated entirely independently of each other in the hybrid clones. Two methods were used to detect the presence of EBV DNA sequences in the intracellular DNA of hybrid clones. The 1st method relied on the hybridization of labeled cRNA prepared from virion DNA with DNA from 8 hybrid clones affixed to nitrocellulose filters. The 2nd approach was to hybridize labeled intracellular DNA from 3 hybrid clones to Southern blots of cloned fragments of EBV DNA. These results suggested that the presence of EBV DNA was not sufficient for the expression of either antigen. One stable RANA-positive hybrid cell line contained at least 80% of the EBV genome in the absence of detectable EBNA.

Animals↗
PubMed1981

HLA-A,B antigens Ia-like antigens, and tumor-associated antigens on prostate carcinoma cell lines: serologic and immunochemical analysis with monoclonal antibodies.

Serologic and immunochemical analysis of the antigenic profile of the 2 human prostate carcinoma cell lines DU-145 and H494 with a battery of monoclonal antibodies has shown that both cell lines express HLA-A,B alloantigens and the 94,000 m.w. tumor-associated glycoprotein recognized by the monoclonal antibody 376.96S. In addition, the cell line H494 unexpectedly expresses Ia-like antigens, which are similar in their antigenic profile and structure to B lymphoid cell derived Ia-like antigens. Both Ia-like antigens and tumor-associated antigens can function as targets of cell-dependent lysis mediated by the corresponding monoclonal antibodies.

Antibodies↗
PubMed1981

Structural properties and tissue distribution of the antigen recognized by the monoclonal antibody 653.40S to human melanoma cells.

The hybridoma 653.40S, constructed with splenocytes from an inbred BALB/c mouse immunized with cultured human melanoma cells, secreted an antibody that had been shown to recognize an antigenic determinant restricted to human melanoma cell lines. The monoclonal antibody (MoAb) 653.40S showed immunoprecipitation of two glycopolypeptides synthesized by melanoma cells, one with the apparent molecular weight of 280,000 and the other one with a molecular weight larger than 500.000. These two glycopolypeptides were not bridged by disulfide bonds and were peripheral rather than integral to the plasma cell membrane. Comparison of the reactivity of cells of the melanocyte lineage with the MoAb 653.40S and with the MoAb Q5/13 to human Ia-like antigens showed that the former reacted with proliferating melanocytes and melanoma cells, whereas the latter reacted only with melanoma cells. The MoAb 653.40S did not react with a large variety of surgically removed normal and tumor tissues except for some instances of basal cell and squamous cell carcinomas. These results suggested that double staining of pigmented skin lesions with the MoAb 653.40S and with an MoAb to Ia-like antigens may help to solve controversial diagnosis of melanoma. Furthermore, the MoAb 653.40S may be useful for radioimaging and immunotherapy of melanoma.

Animals↗
PubMed1981

Levels of Ia-like antigen bearing lymphocytes in patients with solid primary tumors.

In patients with different types of solid tumors who had no detectable metastasis and had received no radio- and chemotherapy the levels of Ia-like antigen bearing lymphocytes was determined by indirect immunofluorescence staining of peripheral lymphocytes with xenoantisera to framework determinants of Ia-like antigens. The level of Ia-like antigen bearing lymphocytes was increased in patients with urinary bladder carcinoma, was decreased in patients with carcinoma of the gastrointestinal tract and was within normal ranges in patients with melanoma, carcinomas of the breast, lung and genital tract. In patients with carcinomas of the gastrointestinal tract as well as in patients with carcinoma of lung and genital tract the levels of T lymphocytes measured by rosetting with sheep red blood cells, was reduced while it was not different from normal in other groups of patients. Determination of the level of lymphocyte subpopulations may provide information about the immunocompetence status of patients with solid tumors.

Adult↗
PubMed1981

Ultrastructural alterations in human lymphoblastoid B cell lines treated with tunicamycin.

The ultrastructure of three human lymphoblastoid B cell lines, Raji, RPMI 4098, and WIL-2, was analyzed after the cells were incubated with tunicamycin, and antibiotic that selectively inhibits N-linked glycosylation of macromolecules. After a 24-hour exposure to 1.0 microgram/ml of tunicamycin, the lymphocytes lose their microvilli and become smooth spheres or develop a few blebs. Also, the cells show a dilation of the endoplasmic reticulum and an increase in myelin figures resulting from intracellular membrane accumulation, possibly lysosomal in origin. These ultrastructural alterations are similar to those observed in Tay-Sachs, Fabrey's, and Gaucher's diseases, Type II pneumocytes in viral pneumonitis, certain lysosomal storage diseases, and in aging fibroblasts. Therefore, tunicamycin-treated cells may be a useful model in the correlation of altered ultrastructural pattern in membrane flow with the etiology of certain diseases.

B-Lymphocytes↗